
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Pediatricians should counsel teenagers about emergency contraception and issue advance prescriptions as part of routine care, says the AAP.






